Hydrocortisone tablets: alleged anti-competitive agreements and abusive conduct

The CMA is investigating alleged anti-competitive agreements and abusive conduct with respect to hydrocortisone tablets under Chapters I and II CA98 and Articles 101 and 102 TFEU.